Victory Capital Management
TSHA icon

Victory Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Victory Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
197,578
+1,833
+0.9% +$10.8K ﹤0.01% 1766
2026
Q1 		$875K Sell
195,745
-19
-0% -$88 ﹤0.01% 1891
2025
Q4 		$1.08M Buy
195,764
+170,164
+665% +$826K ﹤0.01% 1796
2025
Q3 		$83.7K Buy
25,600
+108
+0.4% +$306 ﹤0.01% 2311
2025
Q2 		$58.9K Buy
25,492
+6,475
+34% +$14.1K ﹤0.01% 2368
2025
Q1 		$26.4K Buy
19,017
+16
+0.1% +$27 ﹤0.01% 2414
2024
Q4 		$32.9K Sell
19,001
-1,006
-5% -$2.09K ﹤0.01% 2424
2024
Q3 		$40.2K Buy
20,007
+1,945
+11% +$4.27K ﹤0.01% 2405
2024
Q2 		$40.5K Buy
18,062
+1,144
+7% +$3.33K ﹤0.01% 2386
2024
Q1 		$48.6K Buy
16,918
+1,318
+8% +$2.75K ﹤0.01% 2381
2023
Q4 		$27.6K Buy
+15,600
New +$31.1K ﹤0.01% 2489

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's TSHA Position: Q2 2026 in Review

Victory Capital Management increased its Taysha Gene Therapies (TSHA) stake by 0.94% in Q2 2026, buying an estimated $10.8K and bringing the position to 197,578 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

Victory Capital Management first reported a position in TSHA in Q4 2023 and has held it in 11 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Victory Capital Management held 197,578 shares of Taysha Gene Therapies worth $1.35M as of Q2 2026.
  • Victory Capital Management bought 1,833 Taysha Gene Therapies shares in Q2 2026, an estimated $10.8K.
  • Taysha Gene Therapies made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1766 holding.
  • Victory Capital Management first reported a position in Taysha Gene Therapies in Q4 2023 and has held it in 11 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.